10-Q 1 forest10qdec08.htm FOREST LABORATORIES, INC. FORM 10-Q DECEMBER 31, 2008 forest10qdec08.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
__________________________________________

(Mark One)

x 
  
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended December 31, 2008

o
  
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from          to         

Commission File No. 1-5438

FOREST LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)
  
11-1798614
(I.R.S. Employer
Identification Number)
     
909 Third Avenue
New York, New York
(Address of principal executive offices)
  
10022-4731
(Zip code)

(212) 421-7850
(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x      No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company o
   
(Do not check if a smaller reporting company)
  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  o       No  x

Number of shares outstanding of Registrant's Common Stock as of February 5, 2009: 301,612,811

(Quick Links)

     
 
     
   
   
   
   
   
     
 
     
 
     
 
     
     
 
     
 
     
 
     
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 



Condensed Consolidated Balance Sheets
             
(In thousands)
  
December 31, 2008
 (Unaudited)
    
March 31, 2008
  
             
Assets
            
             
Current assets:
            
Cash (including cash equivalent investments of $1,326,337 in December and $833,018 in March)
   $ 1,326,951     $ 833,052  
Marketable securities
     862,886       943,972  
Accounts receivable, less allowance for doubtful accounts of $18,423 in December and $19,882 in March
     428,892       445,987  
Inventories, net
     396,352       425,138  
Deferred income taxes
     219,872       226,095  
Other current assets
     57,826       33,260  
Total current assets
     3,292,779       2,907,504  
                 
Marketable securities
     673,180       663,625  
                 
Property, plant and equipment
     595,097       567,331  
Less: accumulated depreciation
     245,606       217,294  
      349,491       350,037  
Other assets:
                
Goodwill
     14,965       14,965  
License agreements, product rights and other intangibles, less accumulated amortization of $465,994 in December and $421,719 in March
     481,903       527,787  
Deferred income taxes
     90,911       59,778  
Other assets
     1,596       1,671  
Total other assets
     589,375       604,201  
                 
Total assets
   $ 4,904,825     $ 4,525,367  
                 
                 
                 
See notes to condensed consolidated financial statements.
                



FOREST LABORATORIES, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets

             
(In thousands, except for par values)
  
December 31, 2008
 (Unaudited)
    
March 31, 2008
  
             
Liabilities and Stockholders' Equity
            
             
Current liabilities:
            
Accounts payable
   $ 61,407     $ 223,720  
Accrued expenses
     542,536       387,105  
Total current liabilities
     603,943       610,825  
                 
Long-term liabilities:
                
Income tax liabilities
     257,980       198,410  
Deferred income taxes
     833       815  
      258,813       199,225  
                 
Stockholders' equity:
                
Series preferred stock, $1.00 par; shares authorized 1,000; no shares issued or outstanding
                
Common stock, $.10 par; shares authorized 1,000,000; issued 422,266 shares in December and 421,421 shares in March
     42,226       42,142  
Additional paid-in capital
     1,478,679       1,434,172  
Retained earnings
     6,286,474       5,611,493  
Accumulated other comprehensive (loss) income
     ( 14,368 )     34,592  
Treasury stock, at cost (120,653 shares in December and 110,014 shares in March)
     ( 3,750,942 )     ( 3,407,082 )
Total stockholders' equity
     4,042,069       3,715,317  
                 
Total liabilities and stockholders' equity
   $ 4,904,825     $ 4,525,367  
                 
                 
See notes to condensed consolidated financial statements.
                



Condensed Consolidated Statements of Income
(Unaudited)

   
Three Months Ended
    
Nine Months Ended
  
(In thousands, except per share amounts)
  
December 31,
    
December 31,
  
   
2008
    
2007
    
2008
    
2007
  
                         
Net sales
   $ 920,013     $ 918,146     $ 2,739,329     $ 2,603,099  
Contract revenue
     52,433       52,705       153,796       156,395  
Interest income
     24,235       25,862       61,658       77,532  
Other income
     1,274       1,529       2,522       8,450  
      997,955       998,242       2,957,305       2,845,476  
                                 
Costs and expenses:
                                
Cost of sales
     206,654       213,506       608,995       589,738  
Selling, general and administrative
     289,968       285,652       959,184       827,419  
Research and development
     279,051       108,246       537,520       415,892  
      775,673       607,404       2,105,699       1,833,049  
                                 
Income before income tax expense
     222,282       390,838       851,606       1,012,427  
                                 
Income tax expense
     34,307       89,081       176,625       217,264  
                                 
Net income
   $ 187,975     $ 301,757     $ 674,981     $ 795,163  
                                 
Net income per common share:
                                
                                 
Basic
   $ 0.62     $ 0.97     $ 2.22     $ 2.52  
Diluted
   $ 0.62     $ 0.96     $ 2.21     $ 2.51  
                                 
Weighted average number of common shares outstanding:
                                
                                 
Basic
     301,428       312,140       304,262       315,729  
Diluted
     302,056       313,107       305,147       317,279  
                                 
                                 
See notes to condensed consolidated financial statements.
                          


Condensed Consolidated Statements of Comprehensive Income
(Unaudited)

   
Three Months Ended
    
Nine Months Ended
  
(In thousands)
  
 December 31,
    
 December 31,
  
   
2008
    
2007
    
2008
    
2007
  
                         
Net income
   $ 187,975     $ 301,757     $ 674,981     $ 795,163  
                                 
Other comprehensive (loss) income:
                                
Foreign currency translation (losses) gains
     ( 7,299 )     4,622       ( 25,112 )     12,812  
Unrealized losses on securities:
                                
Unrealized holding loss arising
                                
during the period, net of tax
     ( 12,775 )     ( 5,699 )     ( 23,848 )     ( 5,412 )
                                 
Other comprehensive (loss) income
     ( 20,074 )     ( 1,077 )     ( 48,960 )     7,400  
                                 
Comprehensive income
   $ 167,901     $ 300,680     $ 626,021     $ 802,563  
                                 
                                 
See notes to condensed consolidated financial statements.
                          



Condensed Consolidated Statements of Cash Flows
(Unaudited)

   
Nine Months Ended
  
(In thousands)
  
 December 31,
  
   
2008
    
2007
  
Cash flows from operating activities:
            
Net income
   $ 674,981     $ 795,163  
Adjustments to reconcile net income to net cash provided by operating activities:
                
Depreciation
     32,383       34,988  
Amortization and impairments
     44,275       31,789  
Stock-based compensation expense
     31,516       30,719  
Deferred income tax benefit
     ( 24,892 )     ( 24,209 )
Foreign currency transaction gain
     ( 1,392 )     ( 1,420 )
Net change in operating assets and liabilities:
                
Decrease (increase) in:
                
Accounts receivable, net
     17,095       ( 21,732 )
Inventories, net
     28,786       ( 3,979 )
Other current assets
     ( 24,566 )     ( 8,476 )
Other assets
     75       7,889  
Increase (decrease) in
                
Accounts payable
     ( 162,313 )     11,146  
Accrued expenses
     155,431       23,471  
Income taxes liabilities
     59,570       80,574  
Net cash provided by operating activities
     830,949       955,923  
                 
Cash flows from investing activities:
                
Purchase of property, plant and equipment
     ( 33,026 )     ( 23,906 )
Purchase of marketable securities
     ( 1,646,523 )     ( 2,062,330 )
Redemption of marketable securities
     1,718,054       1,720,777  
Purchase of license agreements, product rights and other intangibles
             ( 45,000 )
Net cash provided by (used in) investing activities
     38,505       ( 410,459 )
                 
Cash flows from financing activities:
                
Net proceeds from common stock options exercised by employees under stock option plans
     10,629       25,672  
Tax benefit realized from the exercise of stock options by employees
      2,446        3,442  
Purchase of treasury stock
     ( 343,860 )     ( 356,327 )
Net cash used in financing activities
     ( 330,785 )     ( 327,213 )
                 
Effect of exchange rate changes on cash
     ( 44,770 )     7,795  
Increase in cash and cash equivalents
     493,899       226,046  
Cash and cash equivalents, beginning of period
     833,052       563,663  
Cash and cash equivalents, end of period
   $ 1,326,951     $ 789,709  

             
Supplemental disclosures of cash flow information:
            
             
Cash paid during the period for:
            
Income taxes
   $ 141,691     $ 157,512  
                 
                 
See notes to condensed consolidated financial statements.
                




FOREST LABORATORIES, INC. AND SUBSIDIARIES
(Unaudited)

1.   Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (or GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  In the opinion of Management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation have been included.  Operating results for the nine-month period ended December 31, 2008 are not necessarily indicative of the results that may be expected for the year ending March 31, 2009.  For further information refer to the consolidated financial statements and footnotes thereto incorporated by reference in the Company's Annual Report on Form 10-K for the year ended March 31, 2008.

2.   Accounts Receivable (In thousands):

Accounts receivable, net, consists of the following:

   
December 31, 2008
 (Unaudited)
    
March 31, 2008
  
             
Trade
   $ 326,472     $ 377,779  
Other
     102,420       68,208  
    $ 428,892     $ 445,987  

3.   Inventories (In thousands):

Inventories, net of reserves for obsolescence, consist of the following:

   
December 31, 2008
 (Unaudited)
    
March 31, 2008
  
             
Raw materials
   $ 146,891     $ 234,288  
Work in process
     936       1,360  
Finished goods
     248,525       189,490  
    $ 396,352     $ 425,138  

4.   Fair Value Measurements (In thousands):

In the first quarter of fiscal 2009, the Company adopted Statement of Financial Accounting Standards No. 157 (or SFAS 157), “Fair Value Measurements.”  This pronouncement defines fair value, establishes a framework for measuring fair value under GAAP and requires expanded disclosures about fair value measurements.  SFAS 157 does not require any new fair value measurements, but rather generally applies to other accounting pronouncements that require or permit fair value measurements.  SFAS 157 emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and defines fair value as the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date.  SFAS 157 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost).  These valuation techniques are based upon observable and unobservable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions.  SFAS 157 utilizes a fair value hierarchy that prioritizes inputs to fair value measurement techniques into three broad levels.  The following is a brief description of those three levels:

 
Level 1:
Observable inputs such as quoted prices for identical assets or liabilities in active markets.
     
 
Level 2:
Observable inputs other than quoted prices that are directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.
     
 
Level 3:
Unobservable inputs that reflect the reporting entity’s own assumptions.

The Financial Accounting Standards Board (or FASB) issued FSP 157-2 which delayed the effective date of SFAS 157 for all non-financial assets and liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis, until the beginning of fiscal 2010.  In October 2008, the FASB issued FSP 157-3, “Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active.”  FSP 157-3 clarifies the application of SFAS 157 in a market that is not active and provides an example to illustrate key considerations in determining the fair value of a financial asset when the market for that financial asset is not active.  FSP 157-3 is effective upon issuance, including prior periods for which financial statements have not been issued.  The Company’s financial assets adjusted to fair value at December 31, 2008 are its commercial paper investments included in cash and cash equivalents, money market accounts, municipal bonds and notes, variable rate demand notes, floating rate notes and auction rate securities (or ARS).  These assets are subject to the measurement and disclosure requirements of SFAS 157.  The Company adjusts the value of these instruments to fair value each reporting period.  No adjustment to retained earnings resulted from the adoption of SFAS 157.

 
The following table presents the level within the fair value hierarchy at which the Company’s financial assets are carried at fair value and measured on a recurring basis:

Description
  
Fair Value at
December 31, 2008
    
Quoted Prices in Active Markets for Identical Assets
  (Level 1)
    
Significant Other Observable Market Inputs
 (Level 2) 
    
Unobservable Market Inputs
 (Level 3)
  
                         
Money market accounts
   $ 1,090,410     $ 1,090,410              
Municipal bonds and notes
     196,125             $ 196,125        
Commercial paper
     782,950       394,663       388,287        
Variable rate demand notes
     162,864               162,864        
Floating rate notes
     411,959       248,473       163,486          
Auction rate securities
     36,889                     $ 36,889  

As of December 31, 2008, the Company has determined the value of the ARS portfolio based upon a discounted cash flow model.  The assumptions used in the valuation model include estimates for interest rates, timing and the amount of cash flows and expected holding periods for the ARS.  As a result of this analysis, for the three months ended December 31, 2008, the Company recorded a temporary impairment loss of $1,906 relating to the ARS portfolio.  The following table presents a reconciliation of the Level 3 investments measured at fair value on a recurring basis using unobservable inputs.

   
Three Months Ended December 31, 2008
  
       
Transfers to Level 3
   $ 38,795  
Gains and losses reported in accumulated other comprehensive income
     ( 1,906 ) 
Balance at December 31, 2008
   $ 36,889  

There were no purchases, sales or material realized gains or losses associated within the Level 3 ARS during the three or nine months ended December 31, 2008.

Money market accounts are included in cash and cash equivalents on the accompanying balance sheets and are classified as Level 1 assets.  Certain commercial paper and floating rate note investments are also classified as Level 1 assets because they consist of publicly traded securities which are priced and actively traded on a daily basis.
 
Certain of the Company’s commercial paper and floating rate notes and all of the Company’s variable rate notes and municipal bonds and notes are based on Level 2 inputs in the SFAS 157 fair value hierarchy.

The Company holds investments in ARS amounting to $36,889 (with underlying maturities from 23 to 33.4 years) of which $23,500 are collateralized by student loans.  Substantially all such collateral in the aggregate is guaranteed by the U.S. government under the Federal Family Education Loan Program.  The balance of the ARS investments of $13,389 are issued by local municipal governments.  Liquidity for these securities was normally dependent on an auction process that resets the applicable interest rate at pre-determined intervals, ranging from 7 to 35 days.  Beginning in February 2008, the auctions for the ARS held by the Company and others were unsuccessful, requiring the Company to continue to hold them beyond their typical auction reset dates.  Auctions fail when there is insufficient demand.  However, this does not represent a default by the issuer of the security.  Upon an auction’s failure, the interest rates reset based on a formula contained in the security.  The rate is generally equal to or higher than the current market rate for similar securities.  The securities will continue to accrue interest and be auctioned until one of the following occurs:  the auction succeeds; the issuer calls the securities; or the securities mature.

The Company classifies the ARS as non-current assets held for sale under the heading “Marketable securities” in the Company’s balance sheets at fair value.  As of December 31, 2008, the Company has changed the classification of the ARS portfolio from Level 2 to Level 3 within the fair value hierarchy due to the lack of observable inputs and continued absence of trading activity during the three-month period.


5.   Net Income Per Share (In thousands):

A reconciliation of shares used in calculating basic and diluted net income per share follows:

   
Three Months Ended
    
Nine Months Ended
  
   
December 31,
    
December 31,
  
   
2008
    
2007
    
2008
    
2007
  
Basic
     301,428       312,140       304,262       315,729  
Effect of assumed conversion of employee stock options and restricted stock
     628       967       885       1,550  
Diluted
     302,056       313,107       305,147       317,279  

Options to purchase approximately 18,176 shares of common stock at exercise prices ranging from $24.12 to $76.66 per share and options to purchase approximately 16,041 shares of common stock at exercise prices ranging from $24.12 to $76.66 per share that were outstanding during a portion of the three and nine-month periods ended December 31, 2008, respectively, were not included in the computation of diluted net income per share because they were anti-dilutive.  These options expire through 2018.  Options to purchase approximately 14,516 shares of common stock at exercise prices ranging from $36.50 to $76.66 per share and options to purchase approximately 11,604 shares of common stock at exercise prices ranging from $36.50 to $76.66 per share that were outstanding during a portion of the three and nine-month periods ended December 31, 2007, respectively, were not included in the computation of diluted net income per share because they were anti-dilutive.  These options expire through 2017.

6.   Stock-Based Compensation (In thousands):

In August 2007 the stockholders of the Company voted to adopt the 2007 Equity Incentive Plan (or the 2007 Plan) which replaces and supersedes all prior stock option plans.  Under the 2007 Plan, 13,950 shares were authorized to be issued to employees of the Company and its subsidiaries at prices not less than the fair market value of the common stock at the date of grant.  The 2007 Plan provides for the granting of incentive and nonqualified stock options, restricted stock, stock appreciation rights and stock equivalent units.  These awards generally vest in three to five years.  Stock option grants may be exercisable for up to ten years from the date of issuance.  As of December 31, 2008, 6,343 shares were available for grant.

Compensation expense of $11,262 ($9,270 net of tax) and $31,516 ($26,314 net of tax) was recorded for the three and nine-month periods ended December 31, 2008, respectively.  For the three and nine-month periods ended December 31, 2007, compensation expense of $10,641 ($8,968 net of tax) and $30,719 ($25,964 net of tax) was recorded.  This expense was charged to cost of sales, selling, general and administrative and research and development expense, as appropriate.

The weighted average number of diluted common shares outstanding is reduced by the treasury stock method which, in accordance with the provisions of Statement of Financial Accounting Standards No. 123(R), “Share-Based Payment” takes into consideration the compensation cost attributed to future services not yet recognized.

7.   Business Segment Information (In thousands):

The Company operates in only one segment.  Below is a breakdown of net sales by therapeutic class:

   
Three Months Ended
    
Nine Months Ended
  
   
 December 31,
    
 December 31,
  
   
2008
    
2007
    
2008
    
2007
  
                         
Central nervous system
   $ 829,384     $ 825,843     $ 2,472,816     $ 2,330,320  
Cardiovascular
     25,501       6,478       54,909       21,746  
Other
     65,128       85,825       211,604       251,033  
    $ 920,013     $ 918,146     $ 2,739,329     $ 2,603,099  

8.   Long-Term Debt:

On December 7, 2007, the Company established a $500 million revolving credit facility for the purpose of providing additional financial liquidity for the financing of business development and corporate strategic initiatives.  The facility can be increased up to $750 million based upon agreement with the participating lenders and expires on December 7, 2012.  As of February 5, 2009, the Company has not drawn any funds from the available credit.  The utilization of the revolving credit facility is subject to the adherence to certain financial covenants such as leverage and interest coverage ratios.

9.   Income Taxes (In thousands):

The Company files income tax returns in the United States and certain foreign jurisdictions including Ireland.  The Company’s income tax returns for fiscal years prior to 1999 in most jurisdictions and prior to 2002 in Ireland are no longer subject to review as such fiscal years are generally closed.  Tax authorities in various jurisdictions are in the process of reviewing the Company’s income tax returns for various post-1999 fiscal years, including the Internal Revenue Service (or IRS), which has recently concluded its examination of the Company’s U.S. federal income tax returns for fiscal years 2002 and 2003.

In connection with that examination, in July 2007, the IRS issued a notice of proposed adjustment primarily relating to the Company’s intercompany transfer pricing methodology.  On November 5, 2007, the IRS issued a Revenue Agent Report which seeks to assess approximately $207 million of additional U.S. corporation income tax relating to the examination period, excluding interest and penalties.

The Company continues to disagree with the IRS position and adjustment because it believes that it is inconsistent with applicable tax laws and the Company intends to defend its position vigorously.  In accordance with the Company’s taxpayer appeals rights, a formal written protest of the proposed adjustment has been filed with the IRS and the matter is in administrative appeals.
While the resolution of this issue may result in tax liabilities that are greater or less than the reserves established, Management believes that the ultimate resolution will not have a material effect on the Company’s financial position or liquidity.  If the IRS prevails in a position that increases the U.S. income tax liability in excess of established reserves, it is likely that the IRS could make similar claims for years subsequent to fiscal 2003 which could be material.  However, at this time Management believes that it is unlikely that the ultimate outcome will be determined within the next 12 months.  The Company’s continuing practice is to recognize net interest related to income tax matters in income tax expense.  As of December 31, 2008, the Company had accrued an additional $7,161 in interest for a total of $27,100 related to the resolution of various income tax matters.

The Company’s effective tax rate was 15.4% and 20.7% for the three and nine-month periods ended December 31, 2008, as compared to 22.8% and 21.5% for the same periods last year.  The decrease resulted primarily from the termination of the Company’s co-promotion agreement for Azor™ and other tax matters including the reenactment of the U.S. Federal research and experimentation tax credit on October 3, 2008, which resulted in a favorable impact on the Company's current three and nine-month periods. This was offset by the net impact of one-time discrete tax adjustments related principally to stock-based compensation in prior years and a lower tax benefit on combined upfront licensing fees to Phenomix Corporation (or Phenomix) for dutogliptin and Pierre Fabre Médicament (or Pierre Fabre) for the compound F2695.  Effective tax rates may be affected by ongoing tax audits. 

10.   License Agreements (In thousands):

During the quarter ended June 30, 2008, the Company and its licensing partner Daiichi Sankyo, terminated their co-promotion agreement for Azor.  As a result of terminating the agreement, the Company recorded a one-time charge of approximately $44,100 to selling, general and administrative expense which was composed of a termination fee of approximately $26,600 and $17,500 related to the unamortized portion of the initial upfront payment. 

In October 2008, the Company entered into a collaboration agreement with Phenomix to co-develop and co-promote dutogliptin.  Dutogliptin is Phenomix’ proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor being developed for the treatment of Type II diabetes. Under the terms of the agreement, the Company made a $75,000 upfront payment to Phenomix, which was recorded to research and development expense. 

In December 2008, the Company entered into a collaboration agreement with Pierre Fabre to develop and commercialize F2695, in the United States and Canada for the treatment of depression.  F2695 is a propriety selective norepinephrine and serotonin reuptake inhibitor that is being developed by Pierre Fabre for the treatment of depression and other central nervous system disorders.  Under the terms of the agreement, the Company made an upfront payment to Pierre Fabre of $75,000, which was recorded to research and development expense. 

11.   Contingencies - Securities Litigation (In thousands):

The Company and certain of its officers have been named as defendants in consolidated securities cases brought in the U.S. District Court for the Southern District of New York on behalf of a class of all purchasers of the Company’s securities from August 15, 2002 through July 2, 2004 and consolidated under the caption “In re Forest Laboratories, Inc. Securities Litigation.”  On September 22, 2008, the Company entered into a Memorandum of Understanding (or MOU) setting forth an agreement in principle to settle all claims against all defendants for $65,000.  While the Company expects a majority of such settlement to be funded by insurance and is engaged in discussions with the carriers concerning their liability for the payment, during the September 2008 quarter the Company recorded a reserve of $25,000 in connection with the MOU.  In January 2009, pursuant to a formal Stipulation of Settlement dated December 12, 2008, the Company paid the full amount of the settlement into escrow pending final Court approval of the settlement.  A hearing with respect to such approval is scheduled for April 2009.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
(Dollar amounts in thousands)

Total net revenues were $997,955 for the quarter, essentially unchanged as compared to the same period last year.  For the nine months ended December 2008, net revenues increased due to the continued growth of our key marketed products Lexapro® and Namenda® despite a modest decrease in Lexapro’s market share in the current quarter.  Contributing to this increase were sales of our newest product Bystolic™, a beta-blocker for the treatment of hypertension launched in January 2008.  Net income decreased 37.7% for the quarter and 15.1% for the nine months ended December 2008 primarily due to $150,000 in combined upfront licensing fees in the current quarter to Phenomix Corporation (or Phenomix) for dutogliptin and Pierre Fabre Médicament (or Pierre Fabre) for the compound F2695.  The current nine month period also included a one-time charge in the June quarter of approximately $44,100 as a result of terminating the Azor™ co-promotion agreement with Daiichi Sankyo, (or Sankyo).  The prior nine month period includes a $70,000 upfront licensing payment to Ironwood Pharmaceuticals, Inc. (or Ironwood), for linaclotide.

In October 2008, we entered into a collaboration agreement with Phenomix to co-develop and co-promote dutogliptin.  Dutogliptin is Phenomix’ proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently in Phase III clinical development for Type II diabetes. Under the terms of the agreement, we made a $75,000 upfront payment to Phenomix and are subject to future milestone payments.

In December 2008, we entered into a collaboration agreement with Pierre Fabre to develop and commercialize F2695 in the United States and Canada for the treatment of depression.  F2695 is a propriety selective norepinephrine and serotonin reuptake inhibitor that is being developed by Pierre Fabre for the treatment of depression and other central nervous system disorders.  We will initiate Phase III studies with F2695 in calendar 2009.  Under the terms of the agreement, we made an upfront payment to Pierre Fabre of $75,000 and are subject to future milestone payments.

On January 14, 2009, we received marketing approval for Savella™ (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.  Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function, afflicting as many as six million people in the United States.  We expect Savella to be available in pharmacies by March 2009.
 
Financial Condition and Liquidity

Net current assets increased by $392,157 from March 31, 2008.  Cash and cash equivalents increased from ongoing operations while short-term marketable securities decreased in order to fund the 2007 Repurchase Program.  During the June 2008 quarter, we repurchased 6.6 million shares of common stock at a cost of $231,185 and in the September 2008 quarter we repurchased 3.5 million shares of common stock at a cost of $100,917.  There were no repurchases in the current quarter, leaving 5.7 million shares still available for repurchase under the program.  Short-term marketable securities also decreased due to new product licensing fees of $150,000 in connection with product collaboration agreements with Phenomix and Pierre Fabre.  Of our total cash and marketable securities position at December 31, 2008, 25%, or about $717,000, is domiciled domestically, with the remainder held by our international subsidiaries.  We currently invest funds in variable rate demand notes that have major bank liquidity agreements, municipal bonds and notes, commercial paper including money market instruments, auction rate securities and bank floating rate notes.  These investments are subject to general credit, liquidity and market risks and have been affected by the global credit crisis.  As a result, we have recorded unrealized losses on certain of these investments to Other Comprehensive Income.  We believe these unrealized losses to be temporary in nature.  Trade accounts receivable decreased primarily due to the timing of receipts.  Other accounts receivable increased primarily due to an insurance claim receivable relating to a securities litigation against the Company and certain of our officers, for which all claims have been settled subject to final Court approval, and the settlement amount paid into escrow in January 2009.  Raw materials inventory decreased as we are bringing these balances to more normalized levels.  Finished goods inventory increased in order to support continued demand for our products, including our recently launched beta-blocker, Bystolic. We believe that current inventory levels are adequate to support the growth of our ongoing business.  License agreements, product rights and other intangibles net of accumulated amortization decreased primarily due to the write-off of the Azor license in the June quarter as well as normal amortization.  The change in other current assets and current liabilities was primarily due to timing and normal operating activities.

Property, plant and equipment before accumulated depreciation increased from March 31, 2008, as we continued to make technology investments to expand our principal operating systems to enhance supply chain and salesforce applications.

Management believes that current cash levels, coupled with funds to be generated by ongoing operations, will continue to provide adequate liquidity to facilitate potential acquisitions of products, payment of achieved milestones, capital investments and continued share repurchases.

Results of Operations

Net sales for the current three-month period increased to $920,013 as compared to $918,146 for the same period last year.  Net sales for the nine months ended December 31, 2008 grew 5% to $2,739,329, primarily due to strong sales of Lexapro, Namenda and Bystolic.
Lexapro, our SSRI for the treatment of major depressive disorder and generalized anxiety disorder, and our most significant product, had sales of $585,473 and $1,752,466 for the quarter and nine months.  While sales decreased 3% for the current three-month period, sales for the current nine-month period grew 2% as compared to the same periods last year.  The decrease in the current quarter was primarily due to a modest decline in market share.  The Lexapro sales contribution resulted in a decrease of $17,981 and an increase of $37,636 to the net sales change for the respective three and nine-month periods, of which $47,838 and $48,978 were due to volume decreases offset by $29,857 and $86,614 of price increases.  During fiscal 2007 Caraco Pharmaceutical Laboratories, Ltd. (or Caraco), filed an Abbreviated New Drug Application (or ANDA) with a Paragraph IV Certification for a generic equivalent to Lexapro.  We along with our licensing partner H. Lundbeck A/S (or Lundbeck) have filed a lawsuit in the U.S. District Court for the Eastern District of Michigan against Caraco for patent infringement.  A trial date has been established for April 2009.

On January 26, 2009, Caraco filed a single-count declaratory judgment action against us and Lundbeck in the U.S. District Court for the Eastern District of Michigan for non-infringement of U.S. Patent No. 7,420,069 (or the ‘069 patent), which is listed in the FDA’s Orange Book for Lexapro.  This action is similar in nature to the declaratory judgment action that Caraco filed against us and Lundbeck in February 2007 for non-infringement of U.S. patent No. 6,916,941 (or the ‘941 patent).  The ‘069 and ‘941 patents are related to crystalline particles of escitalopram (the active ingredient in Lexapro) having a specific median particle size.  Those cases are distinct from the ongoing litigation between the parties involving U.S. Patent No. RE 34,712 (or the ‘712 patent) which is directed to the escitalopram compound itself and do not impact Forest’s exclusive rights to escitalopram under the ‘712 patent which expires in March 2012.

Sales of Namenda, an N-methyl-D-aspartate (or NMDA) receptor antagonist for the treatment of moderate and severe Alzheimer's disease, grew 10% and 17% in the current quarter and nine months, respectively, and totaled $240,851 and $705,530.  This represents an increase of $22,117 and $102,205 as compared to the same periods last year, of which $9,363 and $58,448 was due to volume and $12,754 and $43,757 was due to price.  During the third quarter of fiscal 2008, we received notification from several companies that they filed ANDAs with Paragraph IV Certifications to obtain approval to market generic equivalents of Namenda.  In January 2008, we along with our licensing partner Merz Pharma GmbH & Co. KgaA filed lawsuits in the U.S. District Court of Delaware against several companies for patent infringement.  Namenda’s patent is set to expire in April 2010.  We have applied for patent term extension which, if granted, would extend Namenda’s patent protection until September 2013.

Bystolic (nebivolol hydrochloride), a beta-blocker indicated for the treatment of hypertension, launched in January 2008, achieved sales of $20,961 and $39,498 in the current quarter and nine months, respectively.  The U.S. composition of matter patent covering nebivolol hydrochloride is licensed from Mylan Inc. and expires in 2020 (Forest has submitted a patent term extension application to extend this patent until 2021).  On January 26, 2007, Janssen Pharmaceutica N.V., the owner of the patent, filed a request with the U.S. Patent and Trademark Office (or USPTO) for re-examination of the patent covering nebivolol hydrochloride.  On November 24, 2008, the USPTO confirmed the validity of all of the previously granted claims.

The remainder of the net sales change for the periods presented was due principally to volume and price fluctuations of our older and non-promoted product lines.
 
Contract revenue for the three and nine months ended December 31, 2008 was $52,433 and $153,796 respectively, compared to $52,705 and $156,395 in the same periods last year primarily due to a decrease in co-promotion income from our co-marketing agreement with Sankyo for Benicar.  Fiscal 2008 was the final year of our active co-promotion activities and we will receive a reduced share of product profits over the remaining six-year term of the agreement, as defined.  Going forward, we will not incur salesforce expenses for this product.

Interest income for the three and nine-month periods ended December 31, 2008 decreased as compared to the same periods last year primarily due to lower average rates of return offset by higher levels of invested funds.  Other income in last year’s nine-month period included a milestone payment received related to our European development program for an inhaled cystic fibrosis product.

Cost of sales as a percentage of net sales was 22.5% and 22.2% for the three and nine-month periods of the current year, respectively as compared with 23.3% and 22.7% for the prior year’s three and nine-month periods.

Selling, general and administrative expenses increased $4,316 and $131,765 for the three and nine-month periods ended December 31, 2008 as compared to the same periods last year.  These increases were primarily due to launch costs for Bystolic and pre-launch costs for Savella, as well as the one-time charge of approximately $44,100 relating to the termination of the Azor co-promotion agreement in the June 2008 quarter.  Additionally, during the September 2008 quarter, we reserved $25,000 in connection with a Memorandum of Understanding setting forth an agreement in principle to settle all claims against all defendants in a securities litigation pending against the Company and certain of our officers.  In January 2009, pursuant to a formal Stipulation of Settlement dated December 12, 2008, we paid the full amount of the settlement into escrow pending final Court approval of the settlement.  A hearing with respect to such approval is scheduled for April 2009.  We expect a majority of such settlement to be funded by insurance.
 
Research and development expense increased $170,805 and $121,628 in the three and nine-month periods ended December 31, 2008 as compared to the same periods last year.  During the current quarter we made two $75,000 upfront licensing payments; the first to Phenomix for dutogliptin and the second to Pierre Fabre for F2695.  Dutogliptin is Phenomix’ proprietary orally administered small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently in Phase III clinical development for Type II diabetes. F2695 is a selective norepinephrine and serotonin reuptake inhibitor for the treatment of patients with depression.  In September 2007 we recorded a $70,000 licensing charge in connection with the collaboration agreement with Ironwood for the right to co-develop and co-market linaclotide.  Linaclotide, which recently began Phase III testing, is being investigated for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.

Research and development expense also reflects the following:

 
·
In December 2007, we submitted a New Drug Application (or NDA) to the FDA for milnacipran in the treatment of fibromyalgia syndrome based on data from two Phase III studies which demonstrated significant therapeutic effects.  On January 14, 2009 we received FDA approval for Savella (milnacipran HCl) for the management of fibromyalgia.  In December 2008, we received positive top-line results from an additional randomized Phase III study completed post NDA submission.
 
 
·
In May 2008, we filed a supplemental New Drug Application (or sNDA) for Lexapro for the additional indication of adolescent depression.  The filing included the results from a Phase III study of Lexapro in the treatment of adolescents aged 12-17, with Major Depressive Disorder, which indicate that patients treated with Lexapro experienced statistically significant improvement in symptoms of depression.  The FDA has set an action date for March 2009 for this sNDA.

 
·
In connection with our acquisition of Cerexa, Inc. in January 2007, we acquired worldwide development and marketing rights (excluding Japan) to ceftaroline, a next generation, broad-spectrum, hospital-based injectable cephalosporin antibiotic with activity against gram-positive bacteria such as MRSA and gram-negative bacteria.  In June 2008, we reported positive results from two globally conducted, multi-center Phase III studies of ceftaroline for complicated skin and skin structure infections.  We are also conducting two Phase III studies for community acquired pneumonia and we anticipate those results by the second quarter of calendar 2009.  The data from these two indications, if supportive, will serve as our planned submission package to the FDA for initial marketing approval.

 
·
In April 2006, we entered into a collaboration agreement with Laboratorios Almirall, S.A. (or Almirall) for the U.S. rights to aclidinium, a novel long-acting muscarinic antagonist which is being developed as an inhaled therapy for the treatment of chronic obstructive pulmonary disease (or COPD).  In September 2008 we received positive results from two Phase III studies assessing the safety and efficacy of aclidinium in moderate to severe COPD.  We expect to meet with the FDA in early calendar 2009 to review these results.  Pending FDA feedback, we plan to file an NDA in late calendar 2009 or early calendar 2010.  We and Almirall are also pursuing the development of a fixed-dose combination of aclidinium and the beta-agonist formoterol, which is currently in Phase II testing.

 
·
During the September 2007 quarter, we entered into a partnership with Ironwood to co-develop and co-market the compound linaclotide for North America.  Linaclotide is currently being investigated for the treatment of constipation-predominant irritable bowel syndrome (or IBS-C) and chronic constipation (or CC).  Based on positive results of a Phase II(b) randomized, double-blind, placebo-controlled studies assessing the safety and efficacy of linaclotide in patients with CC and IBS-C, we have initiated a comprehensive Phase III clinical program.  The CC studies have been initiated and we expect to report top-line data in the fourth quarter of calendar 2009.  The IBS-C trials are anticipated to begin during the first quarter of calendar 2009.

 
·
During the third quarter of fiscal 2005, Forest entered into a collaboration agreement with Gedeon Richter Ltd. (or Richter) for the North American rights to cariprazine and related compounds, being developed as an atypical antipsychotic for the treatment of schizophrenia, bipolar mania and other psychiatric conditions.  In September 2008, we received positive preliminary top-line results from an additional Phase II study of cariprazine in patients with acute mania associated with bipolar disorder.  A review of top-line results of a Phase II study in schizophrenia indicated that cariprazine demonstrated a nominally statistical significant (i.e., not adjusted for multiple comparisons) therapeutic effect compared to placebo in a low-dose arm and a numerical improvement compared to placebo in a high-dose arm that did not reach nominal statistical significance.  Based on the review of the results, we and Richter initiated a Phase II(b) dose-ranging study in schizophrenia patients.  This study is being performed in order to better determine an optimal dose to take into the planned Phase III program.  We expect to report this data in the second half of calendar 2009.

 
·
Regarding Bystolic (nebivolol hydrochloride), we plan to file an sNDA in the first half of calendar 2009 for a new indication of congestive heart failure based on the results of the Phase III Seniors study.

 
·
In February 2008, we received preliminary results of a Phase III study of memantine HCl in a novel once-daily formulation of Namenda for the treatment of moderate to severe Alzheimer’s disease.  The results indicated that patients treated with this formulation experienced statistically significant benefits in cognition and clinical global status compared to placebo.  Based on the results of this study, we intend to prepare an NDA for this new once-daily formulation in the first half of calendar 2009.

 
·
During the second quarter of fiscal 2005, Forest entered into a collaboration agreement with Glenmark Pharmaceuticals Ltd. for the North American development and marketing of GRC 3886, a PDE4 inhibitor for the treatment of asthma and COPD.  We have commenced a Phase II study of this compound for the COPD indication with results expected in the second half of calendar 2009.

Among other research and development projects we continue to support are the following: RGH-896, a compound being developed for the treatment of chronic pain and other CNS conditions; a series of novel compounds that target group 1 metabotropic glutamate receptors (mGLUR1/5) and NXL104, a novel intravenous beta-lactamase inhibitor being developed in combination with ceftaroline.  In addition, we have entered into several collaborations to conduct pre-clinical drug discovery.

Our effective tax rate was 15.4% and 20.7% for the respective three and nine-month periods ended December 31, 2008, as compared to 22.8% and 21.5% for the same periods last year.  The decrease resulted primarily from the termination of our co-promotion agreement for Azor and other tax matters including the reenactment of the U.S. Federal research and experimentation tax credit on October 3, 2008, which resulted in a favorable impact on our current three and nine-month periods. This was offset by the net impact of one-time discrete tax adjustments related principally to stock-based compensation in prior years and a lower tax benefit on combined upfront licensing fees to Phenomix for dutogliptin and Pierre Fabre for the compound F2695.  Effective tax rates can be affected by ongoing tax audits.

In connection with our previously reported adoption of the provisions of Financial Accounting Standards Board Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109”, we accrued an additional $7,161 in interest related to unrecognized tax matters totaling $27,100 for the resolution of various income tax matters.

We expect to continue our profitability in the current fiscal year with continued growth in our principal promoted products.

Inflation has not had a material effect on our operations for the periods presented.
 
Critical Accounting Policies

The following accounting policies are important in understanding our financial condition and results of operations and should be considered an integral part of the financial review.  Refer to the notes to the consolidated financial statements for additional policies.

Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and of revenues and expenses during the reporting period.  Estimates are made when accounting for sales allowances, returns, rebates and other pricing adjustments, depreciation, amortization and certain contingencies.  Forest is subject to risks and uncertainties, which may include but are not limited to competition, federal or local legislation and regulations, litigation and overall changes in the healthcare environment that may cause actual results to vary from estimates.  We review all significant estimates affecting the financial statements on a recurring basis and record the effect of any adjustments when necessary.  Certain of these risks, uncertainties and assumptions are discussed further under the section entitled "Forward Looking Statements."

Revenue Recognition

Revenues are recorded in the period the merchandise is shipped.  As is typical in the pharmaceutical industry, gross product sales are subject to a variety of deductions, primarily representing rebates and discounts to government agencies, wholesalers and managed care organizations.  These deductions represent estimates of the related liabilities and, as such, judgment is required when estimating the impact of these sales deductions on gross sales for a reporting period.  Historically, our adjustments for actual future settlements have not been material, and have resulted in either a net increase or a net decrease to net income.  If estimates are not representative of actual settlement, results could be materially affected.  Provisions for estimated sales allowances, returns, rebates and other pricing adjustments are accrued at the time revenues are recognized as a direct reduction of such revenue.

The accruals are estimated based on available information, including third party data, regarding the portion of sales on which rebates and discounts can be earned, adjusted as appropriate for specific known events and the prevailing contractual discount rate.  Provisions are reflected either as a direct reduction to accounts receivable or, to the extent that they are due to entities other than customers, as accrued expenses.  Adjustments to estimates are recorded when customer credits are issued or payments are made to third parties.

The sensitivity of estimates can vary by program and type of customer.  However, estimates associated with Medicaid and contract rebates are most at risk for adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can range up to one year.  Because of this time lag, in any given quarter, adjustments to actual may incorporate revisions of prior quarters.
 
Provisions for Medicaid and contract rebates during a period are recorded based upon the actual historical experience ratio of rebates paid and actual prescriptions written.  The experience ratio is applied to the period's sales to determine the rebate accrual and related expense.  This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable.  As appropriate, we will adjust the ratio to more closely match the current experience or expected future experience.  In assessing this ratio, we consider current contract terms, such as the effect of changes in formulary status, discount rate and utilization trends.  Periodically, the accrual is adjusted based upon actual payments made for rebates.  If the ratio is not indicative of future experience, results could be affected.  Rebate accruals for Medicaid were $27,463 at December 31, 2008 and $26,910 at December 31, 2007.  Commercial discounts and other rebate accruals were $164,655 at December 31, 2008 and $130,409 at December 31, 2007.  These and other rebate accruals are established in the period the related revenue was recognized, resulting in a reduction to sales and the establishment of a liability, which is included in accrued expenses.

The following table summarizes the activity for the nine-month period in the accounts related to accrued rebates, sales returns and discounts (In thousands):

   
December 31, 2008
    
December 31, 2007
  
             
Beginning balance
   $ 229,681     $ 208,063  
                 
Provision for rebates
     375,892       317,947  
Changes in estimates
             2,500  
Settlements
     ( 356,734 )     ( 306,782 )
      19,158       13,665  
                 
Provision for returns
     22,432       24,134  
Changes in estimates
                
Settlements
     ( 17,967 )     ( 22,704 )
      4,465       1,430  
                 
Provision for chargebacks and discounts
     225,189       262,915  
Changes in estimates
             ( 7,700 )
Settlements
     ( 226,225 )     ( 266,145 )
      ( 1,036 )     ( 10,930 )
                 
Ending balance
   $ 252,268     $ 212,228  

Deductions for chargebacks (primarily discounts to group purchasing organizations and federal government agencies) closely approximate actual as these deductions are settled generally within 2-3 weeks of incurring the liability.

Forest's policy relating to the supply of inventory at wholesalers is to maintain stocking levels of up to three weeks and to keep monthly levels consistent from year to year, based on patterns of utilization.  We have historically closely monitored wholesale customer stocking levels by purchasing information directly from customers and by obtaining other third party information.  Unusual or unexpected variations in buying patterns or utilizations are investigated.

Sales incentives are generally given in connection with a new product launch.  These sales incentives are recorded as a reduction of revenues and are based on terms fixed at the time goods are shipped.  New product launches may result in expected temporary increases in wholesaler inventories, which as described above, are closely monitored and historically have not resulted in increased product returns.

Forward Looking Statements

Except for the historical information contained herein, the Management Discussion and other portions of this Form 10-Q contain forward looking statements that involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, changes in laws and regulations affecting the healthcare industry, and the risk factors listed from time to time in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended March 31, 2008.

Quantitative and Qualitative Disclosures About Market Risk                                                          

In the normal course of business, operations may be exposed to fluctuations in currency values and interest rates.  These fluctuations can vary the costs of financing, investing and operating transactions.  Because we had no debt and only minimal foreign currency transactions, there was no material impact on earnings due to fluctuations in interest and currency exchange rates.

As of the end of the period covered by this report, the Company conducted an evaluation, under the supervision and with the participation of the principal executive officer and principal financial officer, of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)).  Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.  There was no change in the Company's internal control over financial reporting during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.



Forest is party to certain legal proceedings described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2008 and our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2008 and September 30, 2008.

We have previously reported reaching an agreement in principle to settle the litigation described in our periodic reports and captioned “In re Forest Laboratories, Inc. Securities Litigation” for a payment of $65 million.  On December 12, 2008, we entered into a definitive Stipulation of Settlement pursuant to which we have agreed to such settlement, subject to final Court approval, and have paid the full amount of such settlement into escrow in January 2009.  A hearing with respect to such approval is scheduled for April 2009.  While we believe a majority of the settlement will be covered by our insurance and we are engaged in discussions with the carriers concerning their liability for the payment, during the September 2008 quarter we recorded a $25 million reserve in connection with the Memorandum of Understanding.



There have been no material changes with respect to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2008 and our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2008 and September 30, 2008.



In May 2006 our Board of Directors (or the Board) authorized a share repurchase program (or the 2007 Repurchase Program) for up to 25 million shares of our common stock.  On August 13, 2007 the Board authorized an additional 10 million shares to be available for repurchase.  No shares were repurchased during the quarter ended December 31, 2008.  As of February 5, 2009, 5.7 million shares were available for repurchase under the 2007 Repurchase Program.

Item 6.
Exhibits
  
     
 
Amended and Restated Change of Control Employment Agreement between Forest and Howard Solomon dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and Lawrence S. Olanoff, M.D., Ph.D dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and Elaine Hochberg dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and Francis I. Perier, Jr. dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and Marco Taglietti dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and Herschel Weinstein dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and Frank Murdolo dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and David Solomon dated October 29, 2008.
 
Amended and Restated Change of Control Employment Agreement between Forest and Raymond Stafford dated October 29, 2008.
 
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date:  February 6, 2009



Forest Laboratories, Inc.
(Registrant)



/s/ Howard Solomon       
Howard Solomon
Chief Executive Officer



/s/ Francis I. Perier, Jr.              
Francis I. Perier, Jr.
Senior Vice President - Finance and
Chief Financial Officer